Vanda Pharma soars
FiercePharma · 4d
Vanda, despite FDA rejection, swats down another buyout bid from Cycle
The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based company. | The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington,
YAHOO!Finance · 3d
Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals
Cycle Pharmaceuticals reaffirmed its proposal to acquire all of the issued and outstanding shares of Vanda Pharmaceuticals for an all-cash consideration of $8.00 per Vanda share. Cycle said it is making its renewed proposal public for the benefit of Vanda shareholders in light of the Vanda board’s continued refusal to engage following the receipt of multiple premium proposals,
The Business Journals · 3d
D.C. drugmaker Vanda rejects another acquisition offer
The offer came days after regulators turned down a bid from the D.C. company to bring a drug to market. D.C. drugmaker Vanda Pharmaceuticals Inc. said Monday its board has rejected a second unsolicited acquisition proposal from Cycle Group Holdings Ltd.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results